drugset / Trial / NCT06746545
A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.
NaSingle-groupOpen-labelTreatment
Summary
Exploring the efficacy and safety of fruquintinib combined with S-1 for second-line and beyond treatment in patients with advanced colorectal cancer.
Timeline
- Start
- 2025-02-01
- Primary completion
- 2026-08-01
- Completion
- 2027-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fruquintinib | Small molecule | 5 mg | Oral |
| Subject | S-1 | Small molecule | 40 mg | Oral |
| Subject | S-1 | Small molecule | 60 mg | Oral |